drugset
drugset / Trial / NCT00476931

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00476931 ↗

Phase 2 Completed 91 enrolled Sangamo Therapeutics
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.

Timeline

Start
2007-05
Primary completion
2010-07
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SB-509 Unknown 60 mg —

Indications

diabetic polyneuropathy type 1 diabetes mellitus type 2 diabetes mellitus